Quotient Wealth Partners LLC Has $590,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Quotient Wealth Partners LLC lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 19.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,601 shares of the medical instruments supplier’s stock after selling 609 shares during the period. Quotient Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $590,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Livelsberger Financial Advisory acquired a new position in Becton, Dickinson and Company in the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC acquired a new position in Becton, Dickinson and Company in the third quarter worth approximately $33,000. Tompkins Financial Corp lifted its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the last quarter. Sound Income Strategies LLC grew its position in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares in the last quarter. Finally, Kennebec Savings Bank acquired a new stake in shares of Becton, Dickinson and Company in the third quarter worth $46,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BDX. Piper Sandler increased their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $283.00.

Becton, Dickinson and Company Stock Up 1.3 %

NYSE:BDX opened at $230.22 on Monday. The stock’s fifty day moving average price is $232.07 and its two-hundred day moving average price is $234.04. The company has a market cap of $66.77 billion, a price-to-earnings ratio of 38.24, a P/E/G ratio of 1.65 and a beta of 0.40. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, analysts anticipate that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a share buyback program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Roland Goette sold 638 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.